Updated Testing Guidelines Make More Women Eligible for Herceptin, yet Benefit Uncertain

ROCHESTER, Minn. — Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology. Cancers that have an excess of HER2 protein or extra copies of th e HER2 gene are called [...]
Source: Mayo Clinic Research News - Category: Research Source Type: news